2024
Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications
Guerrero R, Dorji T, Harris R, Shoulders M, Ogbunugafor C. Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications. ELife 2024, 12: rp88480. PMID: 38833384, PMCID: PMC11149929, DOI: 10.7554/elife.88480.Peer-Reviewed Original ResearchConceptsDrug targetsAllelic variantsStanding genetic variationEmpirical fitness landscapesFitness landscapeGenetic variationB-lactamasePathogenic variantsTarget proteinsVariant sensitivityB-lactamAllelesDrug-target interactionsPathogensMutationsVariantsDrug environmentMechanistic insightDrug developmentMolecular properties of drugsAntimicrobial applicationsApplication metricsLociVariant variablesPharmacological interventionsEvolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications
Guerrero R, Dorji T, Harris R, Shoulders M, Ogbunugafor C. Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications. ELife 2024, 12 DOI: 10.7554/elife.88480.3.Peer-Reviewed Original ResearchDrug targetsAllelic variantsStanding genetic variationEmpirical fitness landscapesFitness landscapeGenetic variationB-lactamasePathogenic variantsTarget proteinsVariant sensitivityB-lactamAllelesDrug-target interactionsPathogensMutationsVariantsDrug environmentMechanistic insightDruggabilityDrug developmentMolecular properties of drugsAntimicrobial applicationsApplication metricsLociVariant variables
2016
Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance
Ogbunugafor C, Wylie C, Diakite I, Weinreich D, Hartl D. Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance. PLOS Computational Biology 2016, 12: e1004710. PMID: 26808374, PMCID: PMC4726534, DOI: 10.1371/journal.pcbi.1004710.Peer-Reviewed Original ResearchConceptsEvolution of drug resistanceAdaptive landscapeMinimal inhibitory concentrationMutational effectsPatterns of epistasisDrug resistanceDihydrofolate reductaseLandscape topographyDrug environmentEmpirical adaptive landscapesEvolutionary outcomesEvolutionary dynamicsOutcome of drug treatmentInhibitory concentrationPlasmodium falciparum dihydrofolate reductaseMutationsModels of drug resistanceCross-resistance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply